Notably, the loss of function of Keap-1 rendered cancer cells sensitive to NEAA (including Asn) restriction in preclinical animal models30,31, suggesting that combining L-ASP and ICB may be a promising strategy to treat NSCLC with Keap-1 mutations. Here, KEAP1 is linked to cancer.